U.S. FDA approves AbbVie's drug for Parkinson's disease
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill
Read the full story at source →
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill
Read the full story at source →
Post Comment